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Abstract
Treatment with the intraaortic balloon pump (IABP) is the most common form of mechanical support for the failing
heart. Augmentation of diastolic pressure during balloon inflation contributes to the coronary circulation and the
presystolic deflation of the balloon reduces the resistance to systolic output. Consequently, the myocardial work is
reduced. The overall effect of the IABP therapy is an increase in the myocardial oxygen supply/demand ratio and
thus in endocardial viability.
This is an overall synopsis of what we need to know regarding IABP. Furthermore, this review article attempts to
systematically delineate the pathophysiology linked with the hemodynamic consequences of IABP therapy. The
authors also look at the future of the use of the balloon pump and conclude that the positive multi-systemic
hemodynamic regulation during IABP treatment should further justify its use.
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Background
Different forms of support of the failing heart consist of
Cardiopulmonary Bypass Pumps/ ECMOs, internal or
external Counterpulsation and the various modes of
Auxiliary heart pump.
Intraaortic balloon pump (IABP) is a form of in-
ternal counterpulsation, acting as an assisting circu-
latory support device. Diastolic augmentation during
inflation potentially contributes to coronary, cerebral,
and systemic circulation.
According to Freedman et al. [1] presystolic deflation
lowers the impedance to systolic ejection. Myocardial
work and oxygen demand are therefore reduced. The
increase in cardiac output detected with intraaortic
balloon treatment is between 0.5 and 1.0 l per minute.
Primarily the impact of IABP is to increase the
myocardial oxygen supply demand ratio. The effec-
tiveness of Intraaortic balloon counterpulsation on
improving oxygen supply and subsequently left ven-
tricular subendocardial blood flow would be best
appreciated by examining the endocardial viability
ratio [2] in a later chapter.
Development of the idea of counterpulsation
The possibility to alter timing of pressure events during
a heartbeat was conceived by Kantrovitz et al. [3]. Exter-
nal counterpulsatrion simulated when the hemidiaph-
ragm wrapped around the distal portion of the thoracic
aorta and stimulated during each diastole. The diastolic
pressure was increased significantly as compared with
control studies.
Simultaneously other researchers [4–6] experiment
counter pulsation. They used femoral access to remove
blood during systole and then replace it during diastole.
Some haemodynamic impact was observed but the
practical application of the technique failed to pursue.
Preliminary studies with an intraaortic balloon pump
took place in 1961 by S. Moulopoulos and associates [7].
Latex tubing was tied around the end of a polyethylene
catheter with multiple side holes. The distal end of the
catheter was occluded so that the tubing could be
inflated and deflated through the side holes in the cath-
eter. The tubing, the catheter and the balloon formed a
closed system that was filled with carbon dioxide; air
pressure was applied intermittently to the tube in the
cylinder and the carbon dioxide was expelled to inflate
the balloon. The stroke was triggered with the aid of a
timing circuit from the electrocardiogram (ECG) of the
animal. The stroke length and the delay after the R wave* Correspondence: vgraham87@gmail.com
Cardiothoracics Department, Royal Victoria Hospital, Belfast, Northern Ireland
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Parissis et al. Journal of Cardiothoracic Surgery  (2016) 11:122 
DOI 10.1186/s13019-016-0513-0
of the electrocardiogram were preset so that the latex
tubing was inflated during diastole and remained
deflated during systole. Testing their balloon pump in
a mock circulation and canine aorta concluded that it
was possible to increase the diastolic blood flow in
the arterial system and lower the end diastolic arterial
pressure.
The concept of external counter pulsation was intro-
duced by Dennis et al. [8] in 1963. This had become
feasible by application of a G-suit (a diastolic leg com-
pression method) covering over the lower extremity to
mid abdomen, which sequentially inflated during dia-
stole and deflated during systole, synchronous with the
cardiac action.
The first clinical application of a successful treatment
with IABP was reported in 1967. Intra aortic balloon
pumping was advocated successfully in a 45 year old
female who had sustained a myocardial infarction and
was hypotensive, comatose and anuric in severe cardio-
genic shock.
By the early 1970s and after a series of successfully
treated patients with cardiogenic shock (The Kantrowitz-
team had treated 30 patients) the IABP had been convin-
cingly promised to be helpful in acute low cardiac output
state following left ventricular failure.
Buckley et al. [9] looked at the hemodynamic benefit of
the IABP and reported the results of treating the first eight
patients in cardiogenic shock and confirmed that balloon
inflation in diastole augments coronary perfusion and
deflation just before systole markedly reduces resistance
to the left ventricular ejection and thereby reduces cardiac
work and myocardial oxygen consumption.
Mundth and co-workers [10] reported as early as 1970 a
case of a patient who sustained cardiogenic shock fol-
lowing myocardial infarction who was stabilised with
Intraaortic balloon counterpulsation; subsequently under-
went coronary revascularisation and with the support of
the balloon pump has had an uneventful recovery. This
was the first report whereas the application of the
intraaortic balloon pump extended successfully to support
heart failure post coronary artery surgery.
Jacobey et al. [11] following the principles of counter-
pulsation in 1971 reported encouraging results for the
treatment of cardiogenic shock in 18 patients with coun-
terpulsation using an ascending aortic cannula.
In 1971 Feola and associates [12] looked upon the
therapeutic impact of intraaortic balloon pump on a
heart failure animal model. Three levels of successively
worsening heart failure (by means of decrease in cardiac
output and aortic pressure and elevation of the left
ventricular end diastolic pressure) were reproduced. In-
stitution of the IABP support followed by normalisation
of left ventricular end diastolic pressure and left atrial
pressure increased the stroke volume and ejection
fraction as well as improvement of coronary and periph-
eral flow and so tissue perfusion. They concluded that
intraaortic balloon pumping is an effective means of circu-
latory support providing that is being used early in the se-
quence of coronary occlusion -myocardial infarction -acute
left ventricular failure. It is most effective in states of
mild to moderate left ventricular failure. There was no
effectiveness of the balloon pumping during the situ-
ation whereas cardiogenic shock with sustained hypo-
tention for more than 30 min and 50 % drop in cardiac
output, had been ensued.
Krakauer et al. [13] in the beginning of 1971 reported
the experience with the intraaortic balloon in 30 cases
treated for cardiogenic shock due to acute myocardial
infarction refractory to conventional pharmacological
treatment. They stated that counterpulsation could benefi-
cially affect hemodynamic measurements. Ventricular
end-diastolic pressure can be decreased, thereby reducing
myocardial tension with a proportionate decrease in myo-
cardial oxygen consumption. The coronary arterial perfu-
sion pressure is increased and this together with reduced
myocardial tension and decreased systolic ejection time
permits enhancement of coronary blood flow. They con-
cluded that the group of patients treated with balloon
support early following the onset of the shock had a sig-
nificant better prognosis.
In 1972 Bregman and coworkers [14] developed a dual
chamber balloon consisting of a large proximal and a
small distal balloon which inflated first; the idea was to
block distal blood flow and augment flow proximally to
the brain and coronary arteries.
The development of catheters and balloons of polyureth-
ane material enable prolonged periods of counterpulsation.
In 1973 two different groups [15, 16] reported the suc-
cessful utilization of IABP in patients who were unable
to be weaned from cardiopulmonary bypass. Therefore,
IABP support opened a new era in the perioperative
management of patients with ventricular dysfunction
during cardiac surgery.
By 1976 more than 5000 patients with post-cardiotomy
low cardiac output had received IABP treatment in
United States.
Continuous evolution brought a method of insertion of
the balloon catheter percutaneously without the need for
surgical cut down [17, 18]. Invasive Cardiologists then
adopted this method; that transformed the entire field of
IABP due to the aggressive expansion of indications
for use of this device to different subsets of patients
with advanced coronary artery disease unresponsive
to medical management.
During the past decade major mechanical and engin-
eering developments have allowed optimal timing of
counterpulsation and on-line monitoring of blood pres-
sure and cardiac output.
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The description of the balloon pump device
The console
The IABP console delivers a specific volume of gas
through a pneumatic system into a balloon during a
predetermined time interval followed by retrieval of the
gas, (Fig. 1). The console contains:
1) A cylinder of gas source (usually helium).
2) A valve unit, which allows delivery of the gas.
3) A monitor system for acquisition of
electrocardiogram and arterial blood pressure.
4) Control unit which processes the electrocardiogram
and develops a trigger signal; this is used for timing
of balloon inflation and deflation by activating the
valve unit and allowing either opening of the valve
in order to deliver the gas, or closure of the valve
unit in order to stop the gas flow.
The driving gas
Both Helium and Carbon dioxide have been used as
driving gases, however the use of helium has theoretical
advantages according to Hendrickx et al. [19]: These
include the speed of gas entry and retrieval as well as
maintenance of a larger volume of gas within the bal-
loon for a longer period of time; due to lower viscosity
of helium as compared with CO2.
Balloon catheters /sizing
Appropriate /inappropriate sizing/ balloon volume and
aortic “occlusivity”
The size of the aorta is related to patient size, age and
weight.
The ideal balloon for any patient has to have the
length from the left Subclavian artery to the coeliac
artery take off, the inflated diameter 90 to 95 % of that
of the discending aorta and has to be equal in volume to
the volume of blood in the aorta at any given time. The
latter statement confirmed by Kantrowitz and colleaques
who stated that the balloon is limited by the volume of
blood contained within the aorta just prior to inflation
(ie. The aortic volume doubles between a shock mean of
30 to 40 mm of Hg and a normal mean pressure of 80
to 90 mm of Hg). Further increases in pumping volume
result only in distention of the aorta (due to aortic elasti-
city) and not in the effective pumping of the balloon.
IABC usage for adult patients has mainly been limited
(82 % of the cases) to the use of 40 cc balloon, with mem-
brane length (non tapered section plus tapered ends) vary-
ing between different manufacturer from 22 to 27.5 cm
and inflated diameter between 15 to 18 mm, Table 1.
While in many clinical situations volume of 40 cc are
appropriate, it should be said that too large IAB in-
creases vascular morbidity whereas too small IAB re-
duces the cardiac benefit. 50 cc Balloon has been
used in taller patients.
Diastolic augmentation is maximized when stroke vol-
ume is equal to balloon volume. If stroke volume is very
low (ie 25–30 ml) or very high (95–100 ml) augmenta-
tion will be decreased.
Position of the balloon within the aorta
The closer the balloon is to the aortic valve, the greater
the diastolic pressure elevation. It is obvious that local
anatomical factors limit the position of the balloon
within the aortic arch therefore the optimal balloon
position will be that where the tip is situated distal to
the left Subclavian artery take off. The proximal balloon
end should be lying above the renal vessels. Incorrect
balloon position results in reduced diastolic augmen-
tation or vascular morbidity due to direct intimal injury
or plaque distortion and embolization or finally direct
occlusion of the arterial lumen.
Hemodynamic criteria for mechanical circulatory support
Despite adequate preload, max pharmacological support
and IAB pumping:
Fig. 1 Description of the circuit between the patient and the intraaortic balloon pump (IABP). The IABP console includes the following: 1) A gas
cylinder (usually helium, which has a theoretical advantage according to Hendrickx et al [14]; 2) a gas supply unit; 3) a monitoring system for
recording the ECG and blood pressure; 4) a control unit that processes the ECG and generates a triggering signal. The latter unit is used for the
timing of inflation and deflation of the balloon via activation of the valve unit, either opening the valve to supply gas or closing it to interrupt
the gas flow
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Cardiac Index < 1.8lt/min
Systolic arterial pressure < 90 mmHg
LA or RA pressure > 20 mmHg










Following the principle of counterpulsation, the IAB is
deflated during systole which coincides with QRS –T
interval (R wave always triggers balloon deflation). In
this manner balloon inflation during cardiac systole is
prevented. The IAB is inflated during diastole, which
coincides with T-P interval, Fig. 2.
Cardiovascular consequences of IABP
Cardiovascular consequences are mainly due to the
effect on preload and afterload [20]. Balloon inflation
causes “volume displacement” resulting in a change in
coronary circulation with redistribution of blood flow
and alteration of oxygen consumption [21, 22].
Intraaortic balloon counterpulsation is instituted by
insertion of a catheter mounted with a distensible poly-
urethane balloon in the patients descending aorta. He-
lium gas is shuttled from the balloon pump console.
Inflation occurs immediately upon onset of diastole.
Deflation occurs during isometric contraction. In a mech-
anical sense balloon inflation causes volume displacement.
Total or regional blood flow is potentially improved with
counterpulsation. Coronary circulation and perfusion to
the aortic arch trifurcated vessels is potentially increased.
Balloon inflation augments the intrinsic Windkessel effect,
which augments peripheral perfusion [23]. At the time of
deflation intraaortic blood volume is decreased with
concomitant lowering of pressure. This process occurs at
the end of diastole just as isovolumetric contraction is
commencing and reduces the impedance against which
the left ventricle must eject. Therefore decreasing
afterload [24].
Cardiovascular changes in systolic events
Decrease in systolic blood pressure
With proper timing if one compares the systolic pres-
sures of non-assisted beats with systolic pressures fol-
lowing IABP assist one would conclude that intra-aortic
balloon pumping results in a decline in systolic pressure
by up to 10 % [25, 26]. A decrease in aortic systolic pres-
sure in the course of balloon pumping indicates proper
systolic unloading and afterload reduction. According to
Norman et al. [27] an alteration in baroreceptor response
may account for this effect.
Decline in pre-systolic (end–diastolic) aortic pressure
During IABP end diastolic aortic pressure is decreased
up to 30 %; indicating systolic unloading.
Table 1 Intraaortic balloon catheter sizes
Balloon volume Balloon membrane length Inflated diameter
25 cc 180 mm 13 mm
30 cc 230 mm 13.9 mm
34 cc 219 mm 14.7 mm
40 cc 260 mm 15 mm
50 cc 270 mm 18 mm
Fig. 2 Haemodynamic function of the balloon. a ECG. b, c Balloon deflation, corresponding to systole during the cardiac cycle, and inflation,
corresponding to diastole. d Balloon action. e Aortic pressure curve during balloon function. f Aortic pressure
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Decrease of the isometric phase of left ventricular
contraction
The Aortic valve during balloon pumping opens early
therefore the isometric phase of LV contraction is de-
creased. This time interval is proportionally related to
myocardial oxygen consumption [28].
Decrease in left ventricular wall tension and the rate of left
ventricular pressure rise (dp/dt)
According to Urschel and collegues [29] the peak rate of
LV pressure rise decreases with IABP up to 20 % compared
with control values.
Effects in ejection fraction, cardiac output and starling law
for the left ventricle
There is an increase in LV Ejection Fraction during IABP
[30]. Likewise there is an increase in Cardiac Output
between 0.5 and 1.0 Lt/per min or up to 30 % [31, 32].
The Starlings law curve for the left ventricle is affected
by IABP [33]. There is a shift of the curve to the left
showing improvement of the left ventricular function.
This has been used as a prognostic indicator: by enlarged
survivors show a sustained effect while non survivors show
a shift to the right indicating ventricular deterioration.
Cardiovascular changes in diastolic events
LVEDP and volume (preload)
The left ventricular diastolic volume is decreased due to
systolic unloading.
The relation between left ventricular diastolic pressure
change and left ventricular diastolic volume change (LV
stiffness) exhibits a trend towards reduced values [34], a
fact that translates into an improvement in left ventricu-
lar compliance.
Cardiovascular changes in coronary blood flow
IABP and myocardial oxygen supply/demand
The IABP effect on improving myocardial oxygen supply
could be better understood by examining the diastolic
pressure time index (DPTI) and tension time index
(TTI), Fig. 3.
DPTI reflects diastolic and subendocardial blood flow
and depends on aortic diastolic pressure, left ventricular
end diastolic pressure and diastolic duration. DPTI in-
creases with IABP due to an increase in diastolic blood
pressure and a decrease in end diastolic pressure.
The area under the left ventricular systolic pressure
curve, which reflects myocardial oxygen demand, is termed
tension time index (TTI). TTI decreases with balloon defla-
tion due to a decrease in systolic blood pressure.
The ratio DPTI/TTI reflects the relation between
oxygen supply and consumption of the myocardium
representing the Endocardial Viability Ratio (EVR). A
value of 1.0 or higher signifies a normal supply/demand
balance. An EVR of less than 0.7 indicates severe
myocardial ischaemia
Phillips et al. [35] introduced endocardial viability ratio
(EVR) in conjunction with intra aortic balloon and
stated that an increased EVR will reflect the increased
blood flow occurring during augmentation, however
only a period of EVR observation without balloon may
assist in determining prognosis.
Bolooki et al. [36] states that with utilization of IABP
the DPTI/TTI ratio is increased. The EVR index is
useful as a criterion to decide early utilization of IABC
in intra-operative failure.
It has to be clarified that TTI as an index of oxygen
demand only accounts for pressure; on the other hand
myocardial oxygen consumption is a function of force
that is proportional to both pressure and volume, there-
fore although EVR will only reflect the decrease in
pressure IABC produces a decrease in volume as well as
pressure. As a consequence the decrease in myocardial
oxygen consumption will be underestimated.
IABP and coronary artery perfusion
Balloon inflation displaces blood proximally increasing
coronary perfusion by also increasing diastolic pressure
and the diastolic perfusion gradient [37, 38].
There are various animal studies that assessed the
contribution of the intra aortic balloon on myocardial
perfusion. Results were variable. Kern et al. [39] stated
that in animals with normal systemic arterial pressure
intraaortic balloon pumping reduced myocardial oxygen
consumption without significantly changing total co-
ronary flow. In ischaemic animal models with low sys-
temic arterial pressure myocardial oxygen consumption
became dependent on coronary flow. IABP had little
Fig. 3 Effect of the intraaortic balloon pump on myocardial oxygen
supply (DPTI) and demand (TTI). DPTI – diastolic pressure time index;
TTI – tension time index
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effect on perfusion to myocardial regions supplied by
occluded coronary vessels.
Gewirtz et al. [40] undertook a study to determine if
balloon pumping increased flow distal to a severe coron-
ary stenosis, however found that despite using IABP
blood flow distal to the stenosis remained unchanged.
McDonald et al. [41] found that IABC increased
prestenotic but not postenotic flow.
However Folland and associates [42] contradicted this
report. They observed relieved anginal symptoms in a
population with coronary artery disease and concomi-
tant severe aortic disease. They concluded that improve-
ment in coronary flow must occur with pumping.
Freedman and associates [43] called myoconservation
technique the initiation of IABC. He stated that the bal-
loon action stimulated collateral circulation in the area
surrounding the core of myocardial damage. Fuchs et al.
[44] agreed that collateral circulation was encouraged
during diastolic augmentation. Kern and associates [45]
assessed intracoronary flow velocity during catheterization
in 12 patients treated with IABC. Diastolic flow velocity
time integral was recorded; the greatest increase in dia-
stolic flow velocity time integral occurred in patients with
a baseline systolic pressure of <90 mmHg. They concluded
that IABC augments proximal coronary blood flow vel-
ocity by doubling the coronary flow velocity integral.
During counterpulsation aortic end diastolic pressure
is lowered. Applying Laplaces low, lowering of aortic
end diastolic pressure during static work (refers to devel-
opment and maintenance of ventricular pressure before
opening of the aortic valve) will decrease the amount of
tension generated at the time the aortic valve opens.
Therefore reducing myocardial oxygen consumption.
Akyurekli et al. [46] undertook a study to determine
the systolic unloading effects of IABC independent of
diastolic augmentation. This was carried out by counter-
pulsating dogs while their coronary arteries were perfused
from an extracorporeal source. The perfusion pressure
was lowered to produce acute cardiac failure. When IABC
was instituted, systolic unloading (a reduction in left
ventricular sustolic pressure) was evident in normotensive
states, but not in hypotensive states (coronary perfusion
pressure < 80 mmHg). During hypotension, aortic compli-
ance increases which causes the aortic wall to expand with
inflation of the balloon, therefore blood volume displace-
ment does not occur. Moreover at the time of deflation,
aortic pressure will not be lowered. Static work and myo-
cardial oxygen consumption will therefore not be lowered.
IABC and peripheral blood flow
Peripheral blood flow is determined by pressure, re-
sistance, length and viscosity. Balloon inflation during
diastole increases the arterial pressure, which increases
the arterial-venous gradient and thus improves flow. In
addition balloon inflation in diastole displaces stroke
volume and thus activation of the aortic baroreceptors
inhibits the medullary vasoconstrictor reflex. Peripheral
resistance decreases, which, as demonstrated by Poiseuilles
low improves blood flow.
The impact of IABC on splachnic blood flow has also
been studied. Landreneau et al. [47] studied the effects of
intraaortic balloon pump assist upon splahnic blood flow
during sustained hemorrhagic shock and following vol-
ume resuscitation. The IABP group was found to have a
return to preshock splachnic visceral perfusion without
the hyperemic reperfusion phenomenon seen in control
animals. They concluded that IABPC during hemorrhagic
shock appears to improve vasomotor control of splachnic
blood flow by eliminating the hyperemic reperfusion
phenomenon resulting in less reperfusion injury.
The effects of IABP upon postoperative renal func-
tion, was studied by Ahmed et al. [48]; they showed
postoperative improvement in human renal perfusion
during counterpulsation.
Swartz et al. [49] studied the influence of juxtarenal bal-
loon position on renal blood flow. They found a 66 % mean
decrease in flow while the IABP was in the renal position.
Weber and Janicki landmark paper
This paper is worth mentioned because it outlines the
variables that influence diastolic pressure augmentation
during balloon inflation [50]. The variables are:
1) Balloon position: The closer to the Aortic valve the
greater the diastolic pressure elevation.
2) Balloon Volume: When the balloon volume is
equal to the stroke volume the diastolic
augmentation is maximized.
3) Balloon diameter and occlusivity: The greatest
augmentation occurs with complete aortic occlusion.
4) Balloon Configuration/Driving gas & Timing.
5) Stroke volume: If stroke volume is less than 25 ml
little diastolic augmentation can be expected.
6) Arterial pressure: The significance of aortic elasticity
is illustrated by the fact that aortic volume doubles
between a mean arterial pressure of 30 mmHg and a
normal mean pressure of 90 mmHg. Our group [51]
calculated an algorithm for optimal balloon sizing in
order to improve diastolic augmentation and
minimise patient-balloon mismatching.
Indications
Overall incidence of IABP utilization
The incidence of IABP treatment following Cardiac surgery
is reported to be around 7 % in various units. This of course
is dependent on the case mix and stratifying patients
according to the Euroscore, one would obviously suggest
that IABP usage correlates with ascending scoring.
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According to various reports, Poor LV function, His-
tory of Myocardial Infarction, Female sex, Diabetes
mellitus, Peripheral Vascular Disease and also Left Main
Stem Disease are incremental risk factors for IABP
utilization.
The unique physiological balance of benefits of IABP,
include support of the coronary circulation [52, 53], as
well as reduction in left ventricular stress and reduction
in cardiac work-load [54].
The indications for use of an IABP involve two areas:
1) Temporary support of the left ventricular function
due to cardiac failure, due to myocardial infarction
or due to intraoperative injury.
2) Improvement in the oxygen supply/demand balance
to decrease the extent of the ischaemic zone and to
preserve myocardial viability.
However the efficacy of IABP is dependent upon the
phase of myocardial ischaemia or the time elapsed from
initiation of myocardial infarction as well as the stage of
left ventricular function.
The value of the balloon pump as a circulatory assist
device in the treatment of cardiogenic shock is well
established [55–57]. Singh et al. [58] suggested criteria
for which IABC would be most successful:
1) Triple Vessel disease with moderately preserved left
ventricular function and good distal targets.
2) Significant mechanical lesions such as mitral
insufficiency or ischaemic ventricular septal defect.
IABP following unstable angina refractory to medical
measurements
Various clinicians must agree that during ischaemic epi-
sodes there is a potential window of opportunity were
adequate hemodynamic support would ensure that ad-
equate myocardium would remain viable to allow resump-
tion of function, following coronary artery bypass grafting
[59, 60]. This is the concept of myoconservation and
where the intraaortic balloon pump exerts major impact.
Gold and associates [61] showed that the usage of
IABP abolishes the pain, ameliorates ST segment ele-
vation and prevents left ventricular tachyarrhytmia.
The same group showed that [62] if the balloon treat-
ment was followed with a CABG then outcome was
statistically better than if the balloon treatment had
not been instituted.
In unstable patients especially in the presence of left
ventricular dysfunction, the use of IABP allows safe per-
formance of diagnostic studies followed by surgical
intervention. Zhang et al. [63] agree that following those
lines of treatment, the operative mortality and the inci-
dence of peri-operative infarction is less.
Langou and associates [64] report in 75 patients follow-
ing the same regimen they had a 5.3 % operative mortality
and a 6.6 % perioperative infarction rate. Furthermore a
study of 55 patients with a similar presentation who were
operated on without IABP, 14.5 % suffered operative death
and 29 % had perioperative infarction.
Although the majority are not controlled non-matched
series, they however still indicate that patients who are
refractory to maximal medical therapy can be operated
on with IABP stabilization with a low operative mortality
and a low peri-operative infarction rate [65, 66]. Incre-
mental risk factors for death include the subgroup of
patients with poor left ventricular function, left main
stem disease, left ventricular hypertrophy, unfavourable
coronary anatomy, diabetic obese females and concomi-
tant end-stage aortic valve disease.
IABP following myocardial infarction
In Theory, IABP could be used during acute myocardial
infarction in order to decrease the size of the infarct, to
support the cardiac function, to prevent infarct extension
and to reduce complications associated with the event.
Miller and associates [67] published their clinical
experience at St. Louis University with a series of 50
consecutive IABP patients. 33 patients (66 %) underwent
IABP due to myocardial infarction. Chest pain was to-
tally relieved in 29 patients (94 %) with improved
hemodynamics in 46 of 50 patients (92 %). 19 patients
(38 %) died, including 13 of the 33 patients admitted
with acute myocardial infarction.
O Rourke et al. examined the effects of IABP on 26
patients with post acute myocardial infarction heart
failure. The first group (n = 12 patients) experienced
ischaemic pain. Ischaemic pain was not persistent in
the second group (n = 14 patients). With institution of
IABP more pronounced hemodynamic improvement
exhibited in-group I.
Effects on ischaemic pain were impressive; pain was
abolished within minutes for 11 patients and hours
for one patient. Only one hospital death occurred in
group I. Of the 14 patients in group II, 8 hospital
deaths occurred.
The same group of investigators [68] in a randomised
clinical study looked at the effects of IABP on post-
myocardial infarction pump failure and showed no benefi-
cial effects on definable end points. Therefore, in patients
with acute infarction IABP is not employed except as a
supportive measure to be followed by a myocardial revascu-
larization procedure; when for example there is develo-
pment of cardiogenic shock or if any of the mechanical
complications following myocardial infarction have oc-
curred. Once there are reasons for revascularization, IABP
may be beneficial in decreasing the size of infarction and
decreasing operative mortality [69].
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In patients with acute myocardial infarction DeWood
et al. [70] reported results with 40 patients treated with
IABP for cardiogenic shock following myocardial infarc-
tion. Group I was treated with IABP and Group II with
IABP and coronary artery bypass grafting. In hospital
mortality between group I and II was 71 % versus 47 %.
The portion of Group II that underwent treatment
within 16 h from the onset of symptoms had a lower
mortality (25 %) than the portion of Group II that
underwent surgery more than 18 h after the onset of
symptoms.(71 %).
Patients who have acute occlusion (coronary dissection
or occlusion due to plaque rupture) of a major branch of
the left coronary artery due to percutaneous intervention
would benefit from IABP followed by emergency revas-
cularization [71, 72].
IABP for ventricular arrythmias
In patients with acute myocardial ischaemia when tachy-
arrhythmia is refractory to second or third line antiar-
rhythmic therapy IABP treatment should be instituted
[73] followed by cardiac catheterisation and coronary
artery bypass grafting.
Almost all the ventricular dysrhythmias due to ischaemia
are temporarily controllable with medication; therefore few
patients would require IABP prior to a revascularization
procedure. There is, however a role for using IABP in
patients who have an unstable rhythm due to myocardial
infarction early after myocardial revascularization.
Patients with ventricular aneurysms and arrhythmias
with triple vessel disease amenable to bypass grafting
have shown good survival results, however arrhythmia
has persisted in 30 % of the cases [74] unless some form
of aneurysm repair is carried out [75, 76].
IABP support for acute ischaemic mitral incompetence
Most frequently involves the posterior papillary muscle
and the responsible coronary artery by 80 % is the right
coronary artery. According to Chen et al. [77] early
mortality is high in these patients (21 %).
IABP should be used in patients who have slipped into
cardiogenic shock following post-infarction MR. This
would allow haemodynamic stability in order to permit
left ventricular catheter studies to be followed by mitral
valve replacement. Concomitant bypass improves early
and late survival [78, 79].
IABP support for acute ischaemic rapture of ventricular
septum
In the majority of cases with cardiogenic shock pulmonary
congestion ensues [80]. According to Khalid and colleagues
[81] deterioration of the patients clinical condition is
dependent upon the extent of involvement of the right
ventricle and also the function of the left ventricle.
Poulsen et al. [82] reported on the extremely poor
outcomes, with in-hospital mortality rates of about
45 % for surgically treated patients and 90 % for
those treated medically.
IABP treatment during ischaemic rupture of the ven-
tricular septum, increases the mean aortic pressure and
cardiac output and decreases the right ventricular and
pulmonary wedge pressure.
Patients should be operated upon as quickly as possible
and a delay in surgery can lead to multi-systemic organ
failure. These patients are at high risk for operative mortal-
ity and even with prompt surgical management, operative
mortality remains significant because of heart failure and
risk of fatal haemorrhage according to Sharma et al. [83].
Agnihotri and colleagues’ meta-analysis of 17 series
from 1991 to 2009 reported five-year survival rates ran-
ging from 33 % to 65 % especially if concomitant revas-
cularization procedure had been advocated [84, 85].
IABP support during percutaneous coronary intervention
(PCI)
The incidence of utilization of IABP in the course of
cardiac catheterisation is reported by the International
Benchmark Registry to be as high as 1 in 5 as an adjunct
to high-risk PCI.
Various authorities around the world [86] have
adopted a policy of “standby” IABP during angioplasty
procedures in high-risk patients [87]. Treatment with
balloon may be the most effective measure in the first
few minutes following complicated angioplasty.
Relative criteria have been developed for selection of
patients who should be considered for prophylactic
IABP before PCI:
Multi-vessel angioplasty in-patient with hypotension,
Angioplasty of the only functional coronary artery
Left main coronary artery angioplasty unprotected by a
patent graft.
Various rare indications for intra-aortic balloon pump
Bridge to cardiac transplantation
IABP mainly reduces the afterload thus improving the
performance of the failing heart. In a series among 274
heart transplant patients, thirty-seven (28 %) required
IABP as a bridge to transplantation.
High risk cardiac patients who are undergoing general
surgical procedures
Two patients presented by Masaki et al. who underwent
intraperitoneal surgery under the support of intraaortic
balloon pump (IABP). In one patient, the IABP was
inserted urgently because of the development of chest
pain with significant ST depression on arrival in the
operating room [88].
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IABP support in paediatric population
The major problems encountered here are:
1) The small size of the aorta.
2) High elasticity of the aorta, which precludes
effective balloon pumping.
3) Small stroke volume, which precludes balloon
augmentation.
Pollack et al. [89] reported rather disappointing early
experience with IABP support for heart failure following
repair of congenital defects in infancy. However, recent
advances in paediatric IABP technology have made its use
feasible for children of all ages with acceptable morbidity.
In selected groups of children with predominantly left
ventricular failure, IABP has been an effective and lifesaving
adjunct to conventional medical treatment of refractory
low cardiac output. These developments are especially rele-
vant to emerging countries where the cost of ECMO/VAD
is prohibitively high; the use of IABP may be a more cost‐
effective modality in appropriate patients [90].
Pulmonary artery balloon pumping
In theory would be indicated for patients with pulmon-
ary hypertension such as after embolectomy or mitral
valve replacement. Acute infarction involving the right
ventricle would be a relative indication. Despite the ob-
vious theoretical advantages, in reality the results are
equivocal [91].
During sudden cardiac arrest
Combination of IABP with external compression dur-
ing resuscitation theoretically improves coronary and
cerebral perfusion.
Inability to be weaned off cardiopulmonary bypass/post
cardiotomy cardiogenic shock
As early as the beginning of 1970s Berger et al. [92] and
also Goldman and colleagues [93] realized that a major
indication for use of an intra-aortic balloon pump is
cardiac dysfunction with low cardiac output after heart
surgery. The group of patients in whom IABP is deemed
beneficial following unsuccessful separation off the car-
diopulmonary bypass machine, include:
1) Patients with severe left ventricular muscle
dysfunction and low ejection fraction who need an
extensive operative procedure, which does not
improve the cardiac performance immediately.
2) Patients requiring reoperations (redo-grafts) while
they are suffering from an acute left ventricular
dysfunction due to an unstable coronary syndrome.
3) When the ejection fraction in percent is lower than
the end-diastolic pressure in mmHg.
4) Patients with severe long standing aortic stenosis and
compromised ejection fraction especially when there
is a need for associated procedures such as aortic root
enlargement or coronary artery bypass grafting.
5) Patients with severe ischaemic mitral incompetence
and dilated poor left ventricular function.
6) Patients with large left ventricular aneurysms and
low ejection fraction.
7) Patients with left main stem coronary disease and an
acute myocardial infarction in progress.
8) Post-operative right ventricular dysfunction.
Emergency use of IABP after cardiac surgery should be
considered, when: all the causes of incomplete revasculari-
zation have been eliminated & there is a difficulty to wean
from heart lung machine after attempting for 30 min at
flow rates above 500 ml/min, with hypotension and low
cardiac index despite increasing requirements of inotropic
support (Dopamine > 10 mcg/Kg/min).
Utilization of IABP as an emergency measure for
postoperative cardiac failure has consistently produced
a survival rate of around 70 % by various groups such
as Pennington et al. [94]. A 2010 study found a cu-
mulative survival for a group of 2697 patients req-
uiring IABP support post-operatively was 85.2 % at
4 years [95].
Brief summary of IABP complications
IABP complications are resulted during difficult inser-
tion and malposition, prolong IABP stay and due to
patient’s comorbidity such as peripheral vascular disease,
small size patients, use of sheath of IABP and Diabetes.
A paper by Rastan et al. [96] identified IABP mal-
position to be a common finding on post insertion
CT scans. Anatomic to balloon length mismatch was
found in 68.2 % of the cases, with subsequently severe
adverse effects.
Injuries resulting during IABP action could be over-
looked unless catastrophic clinical implications are en-
countered; an important paper by Isner et al. [97]
reviewed a total of 45 necropsy patients who have had
an IABP inserted and who died within 105 days of the
time of balloon insertion. Dissection of the aortoiliac
axis occurred in nine patients and in none of them was
the dissection suspected before death. In 4 out of those
9 patients, insertion occurred without resistance. In one
out of the 3 patients that they had developed arterial
perforation no complication of balloon insertion had
been developed. In 2 out of the 3 patients that they had
developed thrombosis intravascularly no clinical suspi-
cion rose prior to death. Clinically silent arterial emboli
occurred in 3 patients. They concluded that out of the
20 complications (in 16 patients) only 4 (20 %) had been
suspected before death.
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By enlarge, complications are reported to be primarily as-
sociated with the insertion process and prolonged balloon
pumping, rather than removal or post removal monitoring.
Obviously, due to the nature of the IABP, the main
complications relate to vascular injury, with studies
suggesting vascular ischaemic complications of between
8–18 % with major limb ischaemia reported to be less
than 1 % [98–102].
In a study published by our group [103], cold pulse-less
foot was detected in 29.5 % of the cases. The ischemia
resolved either with removal of the balloon (n = 18 pt) or
with thrombectomy (n = 8 pt, 5.8 %). One patient devel-
oped gangrene and required amputation.
Thrombocytopenia, defined as platelets <150,000/mL
or >50 % decrease from baseline, occurred in 57.9 %
of patients.
Among patients undergoing IABP, thrombocytopenia
is generally mild, appears to be unrelated to concomitant
heparin use, and is not associated with an increased risk
of major bleeding or in-hospital death [104, 105].
Rupture of the IABP is rare but can cause gas embol-
ism and potential entrapment of the balloon within the
arterial tree. This was first reported by Rajani et al. [106]
however it is very rare, possibly less than 0.5 %. The pro-
posed mechanism involves mechanical disruption of the
balloon against an atherosclerotic plaque or extensively
calcified aortic wall with resultant perforation and the
negative pressure created during deflation traps blood
within the balloon. The blood rapidly reacts with the
helium causing a hard clot formation, which together
with the tortuous atherosclerotic aortic environment
results in entrapment of a semi-deflated balloon [107].
Finally, Complications of thrombosis and infection are
related to the duration of IABP therapy while the limb
ischemic problems are more a function of the athero-
sclerotic status of the common femoral artery and either
the ratio of balloon catheter diameter to arterial lumen,
or the difficulty of dealing with a severely atherosclerotic
artery with loose plaques or fragility requiring excessive
surgical manipulation.
Conclusions
To summarise, the use of the IABP is justified because
an increase in diastolic pressure during balloon inflation
augments the coronary circulation. Further, pre-systolic
deflation of the balloon reduces the resistance to systolic
output; thusa decrease in myocardial work.
The efficacy of the IABP is reflected by the positive out-
comes of the high number of patients who are weaned
from the device. The success rate is higher for patients, in
whom the device is deployed early, reflecting the reversible
nature of ischaemic pathology and the positive contribution
of the IABP to preventing the cascade of complications of
ischaemic heart disease.
Mechanical assistance to the circulation is a rapidly
developing field. The concept of intervention within the
cardiac cycle in order to improve cardiac performance
has been studied from every angle. Diastolic counterpul-
sation by means of IABP is the direct application how-
ever various manipulations in the systolic phase have
been suggested by different researchers.
Midsystolic counterpulsation
A Spherical balloon introduced into the ascending aorta
with the diameter equal to that of the aorta and inflated
for 80 msec during the middle third of the ejection
phase with main effect to increase the coronary flow.
End systolic counterpulsation
A small balloon introduced into the LV and inflated
for 100 msec during late systole, thus reducing LV re-
sidual volume after cardiac systole and increases LV
capacity for the next contraction. The result may be
an increase in contractility and stroke volume. By
inflating the balloon at the end of diastole the LV end
diastolic pressure increases resulting in improvement
of the stroke volume.
Future developments most likely would involve better
definition of the subgroup of patients requiring IABP
support, clear criteria for weaning and improvement in
catheter technology and in drive consoles.
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